Inotiv

B-NDG knockout mice

NOD.CB17-Prkdcscid IL2rgtm1/BcgenHsd
Order Today
+1 800 793 7287 Online order  

Order code: 126

Description
Health monitoring reports
Pricing
Technical resources

  • Autosomal recessive, single nucleotide polymorphism with Prkdc gene on chromosome 16
  • Coat: Albino
  • Common gamma chain gene (II2rg) interrupted
  • Deficiency in cytokine signaling
  • Deficient in T and B cells
  • High humanization capability
  • Lacks functional receptors for IL-2, IL-4, IL-7, IL-9, IL-15, and IL-21
  • Lacks NK cells
  • Severe lymphocyte development impairment


Origin:

The B-NDG model is a single knockout mouse with an ultra immunodeficient phenotype. The model was generated by Biocytogen by deleting the IL2rg gene from NOD-scid mice.

Prkdc (protein kinase DNA-activated catalytic) null scid mutation is characterized by significantly deficient of functional T cells and B cells.

The Common gamma chain gene (IL2RG) deletion results in a lack of functional receptors for IL-2, IL-4, IL-7, IL-9, IL-15, and IL-21, which results in the lack of functional NK cells.

Envigo, now Inotiv, licensed the mouse model from Biocytogen in 2019, where the model had been maintained. The model is albino.

Diet and Husbandry:
Our rodent models are raised and maintained on Teklad diet, bedding, and enrichment products:

Model Support Services:
Inotiv offers related model support services to deliver research-ready models to your facility:

Available regions:

For pricing information, please contact us using the phone number above.

Research use and related publications

2025 Product guide

Receive a copy of our current research models and services product guide.

Download today  
SCIENCE Surgeon - clinical

SCIENTIFIC

INSIGHTS

Keep up-to-date with the latest industry thinking and scientific insights

Explore today
90-anni-globe-widget

More than 90 years of working together, to build a healthier and safer world

Explore our history
Decoration

Subscribe to updates from Inotiv

Sign up and you’ll receive the latest updates that matter to you, delivered straight to your inbox.
Subscribe now